Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy

Treatment options remain limited for patients with castration-resistant prostate cancer (CRPC). We evaluated eribulin mesylate (E7389), a nontaxane halichondrin B analog microtubule inhibitor, in patients with metastatic CRPC with or without previous taxane exposure. Men with histologically proven C...

Descripción completa

Detalles Bibliográficos
Autores: de Bono, JS, Molife, LR, Sonpavde, G, Maroto, JP, Calvo, E, Cartwright, TH, Loesch, DM, Feit, K, Das, A, Zang, EA, Wanders, J, Agoulnik, S, Petrylak, DP
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2012
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p11384
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=11384
Access Level:acceso abierto
Palabra clave:castrate-resistance
chemotherapy
eribulin mesylate
microtubule inhibitor
prostate cancer
prostate-specific antigen
id ES_fe0de35d7adddb6281b1cf4e94dbc968
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p11384
network_acronym_str ES
network_name_str España
repository_id_str
spelling Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapyde Bono, JSMolife, LRSonpavde, GMaroto, JPCalvo, ECartwright, THLoesch, DMFeit, KDas, AZang, EAWanders, JAgoulnik, SPetrylak, DPcastrate-resistancechemotherapyeribulin mesylatemicrotubule inhibitorprostate cancerprostate-specific antigenTreatment options remain limited for patients with castration-resistant prostate cancer (CRPC). We evaluated eribulin mesylate (E7389), a nontaxane halichondrin B analog microtubule inhibitor, in patients with metastatic CRPC with or without previous taxane exposure. Men with histologically proven CRPC, with or without prior taxane exposure, were enrolled in an open-label, single-arm phase II trial. Patients received eribulin mesylate 1.4 mg/m(2) as a 2- to 5-min i.v. bolus infusion on days 1 and 8 of a 21-day cycle. The primary efficacy end point was prostate-specific antigen (PSA) response rate. In total, 108 patients were assessable for safety (50 were taxane-pretreated) and 105 for efficacy in the per-protocol population. The median age of patients was 71 years and median number of cycles was 4. PSA decreases of >= 50% were achieved in 22.4% and 8.5% of taxane-naive and taxane-pretreated patients, respectively. The most common grade 3/4 adverse event was neutropenia, seen in 22.4% of chemo-naive and 40% of taxane-pretreated men. Grade 3 peripheral neuropathy occurred in none of the taxane-naive patients and 6.0% of taxane-pretreated patients. Eribulin mesylate demonstrated activity and a relatively favorable toxicity profile in metastatic CRPC.ELSEVIER2012info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=11384ANNALS OF ONCOLOGYISSN: 09237534ISSNe: 15698041reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p113842026-06-14T12:41:47Z
dc.title.none.fl_str_mv Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
title Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
spellingShingle Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
de Bono, JS
castrate-resistance
chemotherapy
eribulin mesylate
microtubule inhibitor
prostate cancer
prostate-specific antigen
title_short Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
title_full Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
title_fullStr Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
title_full_unstemmed Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
title_sort Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
dc.creator.none.fl_str_mv de Bono, JS
Molife, LR
Sonpavde, G
Maroto, JP
Calvo, E
Cartwright, TH
Loesch, DM
Feit, K
Das, A
Zang, EA
Wanders, J
Agoulnik, S
Petrylak, DP
author de Bono, JS
author_facet de Bono, JS
Molife, LR
Sonpavde, G
Maroto, JP
Calvo, E
Cartwright, TH
Loesch, DM
Feit, K
Das, A
Zang, EA
Wanders, J
Agoulnik, S
Petrylak, DP
author_role author
author2 Molife, LR
Sonpavde, G
Maroto, JP
Calvo, E
Cartwright, TH
Loesch, DM
Feit, K
Das, A
Zang, EA
Wanders, J
Agoulnik, S
Petrylak, DP
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv castrate-resistance
chemotherapy
eribulin mesylate
microtubule inhibitor
prostate cancer
prostate-specific antigen
topic castrate-resistance
chemotherapy
eribulin mesylate
microtubule inhibitor
prostate cancer
prostate-specific antigen
description Treatment options remain limited for patients with castration-resistant prostate cancer (CRPC). We evaluated eribulin mesylate (E7389), a nontaxane halichondrin B analog microtubule inhibitor, in patients with metastatic CRPC with or without previous taxane exposure. Men with histologically proven CRPC, with or without prior taxane exposure, were enrolled in an open-label, single-arm phase II trial. Patients received eribulin mesylate 1.4 mg/m(2) as a 2- to 5-min i.v. bolus infusion on days 1 and 8 of a 21-day cycle. The primary efficacy end point was prostate-specific antigen (PSA) response rate. In total, 108 patients were assessable for safety (50 were taxane-pretreated) and 105 for efficacy in the per-protocol population. The median age of patients was 71 years and median number of cycles was 4. PSA decreases of >= 50% were achieved in 22.4% and 8.5% of taxane-naive and taxane-pretreated patients, respectively. The most common grade 3/4 adverse event was neutropenia, seen in 22.4% of chemo-naive and 40% of taxane-pretreated men. Grade 3 peripheral neuropathy occurred in none of the taxane-naive patients and 6.0% of taxane-pretreated patients. Eribulin mesylate demonstrated activity and a relatively favorable toxicity profile in metastatic CRPC.
publishDate 2012
dc.date.none.fl_str_mv 2012
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=11384
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=11384
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER
publisher.none.fl_str_mv ELSEVIER
dc.source.none.fl_str_mv ANNALS OF ONCOLOGY
ISSN: 09237534
ISSNe: 15698041
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425650356453376
score 15,811543

Similares en LA Referencia